One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study

NCT03662919 · clinicaltrials.gov ↗

COMPLETED

Status

2274

Enrollment

INDUSTRY

Sponsor class

Conditions

Arthritis, Rheumatoid
Spondylitis, Ankylosing
Arthritis, Psoriatic
Crohn's Disease
Colitis, Ulcerative

Interventions

DRUG: Infliximab
DRUG: Adalimumab

Sponsor

Biogen